AstraZeneca and Takeda enter agreement to develop Parkinson’s disease drug

29-08-2017

AstraZeneca and Takeda have entered into an agreement to develop and commercialise MEDI1341, an alpha-synuclein antibody currently in development as a potential treatment for Parkinson’s disease (PD).


AstraZeneca, Takeda, Parkinson’s disease, collaboration, neuroscience, Mene Pangalos, Emiliangelo Ratti

LSIPR